AstraZeneca : Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) - Form 6-K -March 25, 2024 at 07:31 am EDT

a0626i

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

Massachusetts ,United States ,Australia ,United Kingdom ,Hungary ,Boston ,Cambridge ,Cambridgeshire ,Washington ,Japan ,New Zealand ,America ,Marc Dunoyer ,Seanj Pittock ,Adrian Kemp ,Neuromyelitis Optica ,Histochem Cytochem ,Drug Administration ,Mayo Neuroimmunology Laboratory ,Mayo Clinic Center ,Securities Exchange ,Astrazeneca ,European Union ,Nasdaq ,Investor Relations Team ,Alexion Pharmaceuticals Inc ,Commission File Number ,Company Secretary ,Foreign Issuer ,Securities Exchange Act ,File Number ,Crick Avenue ,Regulationst Rule ,Mayo Clinic ,Multiple Sclerosis ,Autoimmune Neurology ,Neuroimmunology Laboratory ,Chief Executive Officer ,North America ,Expanded Disability Status Scale Score ,Astrazeneca Rare Disease ,Alexion Pharmaceuticals ,Rare Diseases ,Ann Neurol ,Treat Options ,South East ,Neurol Neurosurg ,Neuromyelitis Optica Spectrum Disorder Using ,Safety Study ,Adult Participants With ,Accessed March ,